Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...
NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...
The United States has passed peak obesity, according to new data, suggesting that the sweeping uptake of weight-loss drugs ...
Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to ...
The other GLP-1: A Novo Nordisk spokesperson said all doses of Ozempic and Wegovy, its semaglutide-based diabetes and ...
The FDA determined the shortage of Eli Lilly And Co’s (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
Around the world, obesity rates have been stubbornly climbing for decades, if anything accelerating in recent years. But now newly released data finds that the US adult obesity rate fell by around two ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback